Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer

Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer

Thursday, January 28, 2021
Webinar -- 9:15 AM SGT


Welcome, Introduction, and Baseline Assessment

Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC

  • Overview/introduction to ADCs

Presentation: Activity of ADCs in Clinical Trials for Lung Cancer

  • HER2-altered NSCLC
  • Other ADC targets in NSCLC

Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC

  • Overview of expected global approvals and expanded indications
  • Strategies to bypass EGFR-TKI resistance in NSCLC
  • Managing treatment-related symptoms
  • Case examples illustrating use of ADCs in NSCLC care
  • Future directions: Partnering ADCs with immune checkpoint inhibitors

Panel Discussion and an Audience Question and Answer Session

Summary, Final Thoughts, Posteducation Assessment, and Audience Question and Answer Session


Program Director
Ross Camidge, MD, PhD

Professor of Medicine,
Division of Medical Oncology
University of Colorado

Joel Neal, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Stanford University
Attending Physician
Stanford Cancer Institute
Palo Alto, California

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in integrating emerging antibody–drug conjugate therapies into lung cancer treatment paradigms.

Target Audience
This program is intended for global medical oncologists and other healthcare providers who care for patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify features that affect the efficacy and toxicity of antibody–drug conjugates
  • Assess clinical data for antibody drug conjugates being studied in advanced NSCLC
  • Explain rationale and assessments of HER2 and other antibody drug conjugate targets in NSCLC
  • Evaluate emerging strategies for using antibody-drug conjugates to overcome EGFR TKI resistance


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.